Read our latest press releases, hear our most recent media appearances, and see which upcoming events we are attending.
Subscribe to our social channels to ensure you get our updates, news and announcements as and when they happen.
12 February 2026 Webinar | The frontier AI landscape: Unlocking next-generation opportunities for the UK
MDC’s Professor Chris Molloy, is speaking at 2026 is a unique invitation-only summit focused on a One Health approach to antimicrobial resistance (AMR), hosted by Australia’s National Science Agency, CSIRO, and the Fleming Initiative.
A human focus for 21st century life sciences is a unique and exciting Royal Society Science+ meeting in London 3-4 February, organised by The Alliance for Human Relevant Science. Don’t miss MDC’s Professor Chris Molloy who is taking part in a panel discussion: Panel Discussion Date: Wednesday 4 February 2026 Time: 11:15 AM – 12:15 PM Location: One Birdcage Walk
4 February 2026 – Whether you are early-stage or gearing up for growth, MDC can support you with R&D consultancy for MedTech, HealthTech and BioTech, Innovate UK Growth Voucher opportunities, Investor networks and fundraising strategy, grants, bids and funding advice.
This is the first in a series of radiopharmaceutical blogs from Dr Juliana Maynard. Juliana is an expert imaging scientist with over 20 years’ experience in nuclear medicine and translational imaging.
In this blog, Dr Phil Auckland details how MDC has established a reproducible CRISPR-Cas9 pipeline and generated new tools to better inform nanotherapeutic design
Nanotherapeutics often fail because of Endosomal entrapment. In this blog by Dr Phil Auckland, we explore how MDC are using real-time imaging to reveal why.
Mapping Neurodegeneration: Multi-Omics Insights into Patient Disease and Preclinical Models by Gayle Marshall, Head of Biomarkers and An analytical platform that spans throughput, mechanism, and models to inform LNP design by Phil Auckland, Lead Scientist
See how we can help support you with your next drug discovery project.
Speak to us
